Centogene’s Biodatabank Drives Rare Disease Breakthroughs
Company Announcements

Centogene’s Biodatabank Drives Rare Disease Breakthroughs

Centogene N.V. (CNTG) has released an update.

Centogene N.V. has announced substantial growth in its CENTOGENE Biodatabank, now encompassing insights from over 850,000 patients, aiding the diagnosis of more than 2,500 rare and neurodegenerative diseases. The company has not only expanded its patient database by 13% over the past year but also increased its unique genetic variants by 19%, with contributions from a diverse global patient pool. These advancements support Centogene’s diagnostic capabilities and enhance its collaborations with pharmaceutical companies to expedite drug discovery and development.

For further insights into CNTG stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskCentogene NV Announces Nasdaq Delisting
TheFlyCentogene receives delisting notice from Nasdaq
TheFlyCentogene publishes ROPAD study data on Parkinson’s disease in Brain
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App